Randomized evaluation of ceftazidime or ticarcillin and tobramycin for the treatment of osteomyelitis caused by gram-negative bacilli.
Identifieur interne : 004486 ( Pmc/Checkpoint ); précédent : 004485; suivant : 004487Randomized evaluation of ceftazidime or ticarcillin and tobramycin for the treatment of osteomyelitis caused by gram-negative bacilli.
Auteurs : T G Sheftel ; J T MaderSource :
- Antimicrobial Agents and Chemotherapy [ 0066-4804 ] ; 1986.
Abstract
Ceftazidime, a new cephalosporin with enhanced activity against aerobic gram-negative bacilli, was compared with tobramycin and ticarcillin in a randomized clinical trial. Efficacy and safety were evaluated in 18 patients (17 males, 1 female) with gram-negative osteomyelitis. All organisms were susceptible to the treatment antibiotics(s). There were nine patients treated with tobramycin and ticarcillin for 27 to 62 days (mean, 42 days), and nine patients were treated with 4 g of ceftazidime per day for 26 to 63 days (mean, 45 days). All nine patients receiving tobramycin and ticarcillin had the osteomyelitis arrested after the initial treatment. Follow-up was for 2 to 38 months (mean, 22 months). Of nine patients receiving ceftazidime three were initial treatment failures. Follow-up was for 13 to 31 months (mean, 21 months). A patient receiving ceftazidime had a transient rise in serum glutamic oxalacetic transaminase and serum glutamic pyruvic transaminase. There were three treatment failures in the ceftazidime group; no failures occurred in the group receiving the combination of ticarcillin and tobramycin. A larger series would be required to detect a significant difference between the two treatment groups.
Url:
PubMed: 3524419
PubMed Central: 180374
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
PMC:180374Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Randomized evaluation of ceftazidime or ticarcillin and tobramycin for the treatment of osteomyelitis caused by gram-negative bacilli.</title><author><name sortKey="Sheftel, T G" sort="Sheftel, T G" uniqKey="Sheftel T" first="T G" last="Sheftel">T G Sheftel</name></author><author><name sortKey="Mader, J T" sort="Mader, J T" uniqKey="Mader J" first="J T" last="Mader">J T Mader</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">3524419</idno><idno type="pmc">180374</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC180374</idno><idno type="RBID">PMC:180374</idno><date when="1986">1986</date><idno type="wicri:Area/Pmc/Corpus">001473</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001473</idno><idno type="wicri:Area/Pmc/Curation">001472</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001472</idno><idno type="wicri:Area/Pmc/Checkpoint">004486</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">004486</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Randomized evaluation of ceftazidime or ticarcillin and tobramycin for the treatment of osteomyelitis caused by gram-negative bacilli.</title><author><name sortKey="Sheftel, T G" sort="Sheftel, T G" uniqKey="Sheftel T" first="T G" last="Sheftel">T G Sheftel</name></author><author><name sortKey="Mader, J T" sort="Mader, J T" uniqKey="Mader J" first="J T" last="Mader">J T Mader</name></author></analytic><series><title level="j">Antimicrobial Agents and Chemotherapy</title><idno type="ISSN">0066-4804</idno><idno type="eISSN">1098-6596</idno><imprint><date when="1986">1986</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Ceftazidime, a new cephalosporin with enhanced activity against aerobic gram-negative bacilli, was compared with tobramycin and ticarcillin in a randomized clinical trial. Efficacy and safety were evaluated in 18 patients (17 males, 1 female) with gram-negative osteomyelitis. All organisms were susceptible to the treatment antibiotics(s). There were nine patients treated with tobramycin and ticarcillin for 27 to 62 days (mean, 42 days), and nine patients were treated with 4 g of ceftazidime per day for 26 to 63 days (mean, 45 days). All nine patients receiving tobramycin and ticarcillin had the osteomyelitis arrested after the initial treatment. Follow-up was for 2 to 38 months (mean, 22 months). Of nine patients receiving ceftazidime three were initial treatment failures. Follow-up was for 13 to 31 months (mean, 21 months). A patient receiving ceftazidime had a transient rise in serum glutamic oxalacetic transaminase and serum glutamic pyruvic transaminase. There were three treatment failures in the ceftazidime group; no failures occurred in the group receiving the combination of ticarcillin and tobramycin. A larger series would be required to detect a significant difference between the two treatment groups.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-title>Antimicrobial Agents and Chemotherapy</journal-title><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn></journal-meta><article-meta><article-id pub-id-type="pmid">3524419</article-id><article-id pub-id-type="pmc">180374</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Randomized evaluation of ceftazidime or ticarcillin and tobramycin for the treatment of osteomyelitis caused by gram-negative bacilli.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sheftel</surname><given-names>T G</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mader</surname><given-names>J T</given-names></name></contrib></contrib-group><pub-date pub-type="ppub"><month>1</month><year>1986</year></pub-date><volume>29</volume><issue>1</issue><fpage>112</fpage><lpage>115</lpage><abstract><p>Ceftazidime, a new cephalosporin with enhanced activity against aerobic gram-negative bacilli, was compared with tobramycin and ticarcillin in a randomized clinical trial. Efficacy and safety were evaluated in 18 patients (17 males, 1 female) with gram-negative osteomyelitis. All organisms were susceptible to the treatment antibiotics(s). There were nine patients treated with tobramycin and ticarcillin for 27 to 62 days (mean, 42 days), and nine patients were treated with 4 g of ceftazidime per day for 26 to 63 days (mean, 45 days). All nine patients receiving tobramycin and ticarcillin had the osteomyelitis arrested after the initial treatment. Follow-up was for 2 to 38 months (mean, 22 months). Of nine patients receiving ceftazidime three were initial treatment failures. Follow-up was for 13 to 31 months (mean, 21 months). A patient receiving ceftazidime had a transient rise in serum glutamic oxalacetic transaminase and serum glutamic pyruvic transaminase. There were three treatment failures in the ceftazidime group; no failures occurred in the group receiving the combination of ticarcillin and tobramycin. A larger series would be required to detect a significant difference between the two treatment groups.</p></abstract></article-meta></front></pmc><affiliations><list></list><tree><noCountry><name sortKey="Mader, J T" sort="Mader, J T" uniqKey="Mader J" first="J T" last="Mader">J T Mader</name><name sortKey="Sheftel, T G" sort="Sheftel, T G" uniqKey="Sheftel T" first="T G" last="Sheftel">T G Sheftel</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004486 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 004486 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Checkpoint
|type= RBID
|clé= PMC:180374
|texte= Randomized evaluation of ceftazidime or ticarcillin and tobramycin for the treatment of osteomyelitis caused by gram-negative bacilli.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i -Sk "pubmed:3524419" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |